Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Consensus on optimal use of fixed-duration BTK inhibitor and venetoclax therapy in CLL: A delphi study comparing human expertise and AI methodologies

View Full Paper
Ask AI
Bookmark
Share

Authors

MVMaria Rosaria VillaGNGiuseppe Rodolfo Nunziata

Discussion

Loading...

Member takes

Overview

Delphi consensus reveals key considerations for venetoclax and BTK inhibitor therapy in chronic lymphocytic leukemia patients with comorbidities.

Key Points

  • Overall agreement of over 75% was achieved for ten out of twelve consensus statements.
  • The Delphi panel emphasized the significance of patient comorbidities when selecting BTK inhibitors.
  • Assessment through a modified Delphi process compared human consensus with AI responses.
  • This analysis highlights the necessity of nuanced human judgment in therapeutic decision-making for CLL.

Cite This Study

Villa et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d503https://doi.org/10.1182/blood-2025-7434
View Full Paper
Ask AI
Bookmark
Share